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Abstract  
In this paper, we construct a mathematical model describing immune response to the growth of breast 
cancer cells and investigate the impact of immunotherapy, chemotherapy and biochemotherapy treatments. 
We present a model using coupled ordinary differential equations and are also describing the effect of 
tumor infiltrating lymphocytes (TIL), Interleukin-2 (IL-2) & Interferon alpha (INF-𝛼) on dynamics of 
tumor cells under the influence of immunotherapy, chemotherapy & biochemotherapy. A new & promising 
treatment option biochemotherapy has the potential to help reduce the deaths caused by breast cancer. This 
model is used to evaluate the effects of pulsed application of the drugs. Numerical simulation for some 
cases show that efficiency of these therapies depends on both variation of tumor size & variation of 
parameters among two patients. The biochemotherapy more effective than other therapies. 
Keywords: Immunotherapy, Chemotherapy, Biochemotherapy, Tumor Infg lymphocytes (TIL), 
Interleukin-2 (IL-2) Interferon-alpha (INF-𝛼). 
 
1. Introduction - 
            Cancer is one of the leading causes of death behind only heart disease. The fact that the immune 
system plays an important role in fighting cancer. The malignant properties of cancer differentiate 
malignant tumors from benign tumors which do not grow uncontrollably, directly invade locally (or) distant 
body sites like brain, bone, liver (or) other organs. 
The Cancer Research Institute reports that in 1995, an estimated 1.252.000 cases were diagnosed, with 
547.000 deaths in the United States alone. With new techniques for detection and treatment of cancer, the 
relative survival rate has now risen to 54 percent [5]. Cancer causes 1 in 8 deaths worldwide and is rapidly 
becoming a global pandemic. According to the International Agency for Research on Cancer, there were 
12.7 million new cancer cases in 2008. If rates don’t change, the global cancer burden is expected to nearly 
double to 21.4 million cases and 13.5 million deaths by 2030 [8]. It is significant to explore new treatment 
techniques, in order to reduce the rate of mortality due to cancer in the future. 
A new treatment option, the use of monoclonal antibody drugs, has recently been explored as a possible 
approach to controlling kidney cancer. We have built a system of nonlinear ordinary differential equations 
(ODEs) that model the growth of a kidney tumor & its interaction with host’s immune system. Using this 
model we consider three different types of treatments. 
Immunotherapy (Biotherapy):- Immunotherapy is treatment uses the body’s own immune system to fight 
diseases such as cancer. The main premise is stimulating the patient’s immune system to attack the 
malignant tumor cells that are responsible for the disease. This can be either through immunization of the 
patient in which case the patient’s own immune system is trained to recognize tumor cells as targets to be 
destroyed or through the administration of therapeutic antibodies. 
Immunotherapy includes a wide variety of treatments that work different ways such as: Biologics, 
Monoclonal antibodies, vaccines, gardasil, BCG, etc. There are known three main categories of 
immunotherapy: cytokines, monoclonal antibodies & vaccines. Cytokines are chemicals made by immune 
system cells & play a important role in regulating the growth and activity of other immune system cells & 
blood cells. The most common cytokines are interleukins-2(IL-2) & interferon alpha (INF-α). Both 
cytokines cause these cancers to shrink to less than half their original size in about 10% to 20% of patients. 
Cytokines can also be used as part of some experimental immune techniques. One approach took special 
immune system cells called tumor-infiltrating lymphocytes (𝑇𝐼𝐿𝑆) that can be found within kidney tumors. 
These cells were taken from the tumor after surgery. 
Chemotherapy: - Chemotherapy is a treatment of cancer with one or more cytotoxic antineoplastic drugs 
(chemotherapeutic agents) as part of standardized regimen. This therapy may be given with a curative 
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intent or it may aim to prolong life or to palliate symptoms. It is often used in conjunction with other cancer 
treatments such as radiation therapy or surgery. 
Traditional chemotherapeutic agents act by killing cells that divide rapidly, one of the main properties of 
most cancer cells. This means that Chemotherapy also harms cells that divide rapidly under normal 
circumstances: cells in the bone marrow, digestive tract & hair follicles. Different types of chemo drugs are 
alkylating agent’s antimetabolites antitumor antibiotics, mitotic inhibitors. 
Biochemotherapy: - Biochemotherapy, the combination of chemo and biologic response. Modifiers, was 
developed in the early 1990’s to improve response rates and durate remissions in metastatic melanoma. 
This type of therapy is more effective at extending overall survival than single agent chemo, combination 
chemo (or) single agent immune. 
CELL DIVISION: Following figure represent different types of cells, some of which we use in our model.     
 
   
 
 
2. Mathematical Model – 
 
This mathematical model is based on the de Pillis’s model [6] and Isaeva and Osiopov’s model [7]. For the 
sake of completeness, we outline the assumptions of the original model [6] here: 
1. Tumor grows logistically in the absence of an immune response. NK cells always present in the 
body. 
2. As part of the specific immune response, active tumor-specific CD8+ T cells are only present in 
large numbers when tumor cells are present. 
3. Both NK and CD8+ T-cells are capable of killing tumor cells. Eventually become inactive after 
some number of encounters with tumor cells. 
4. Both NK and CD8+ T-cells respond to tumor cells by expanding and increasing cytolytic activity. 
5. Tumor cells inactivation due to there are present INF-𝛼. We added assumptions are used in the 
development of therapeutic terms. 
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6. The fraction of the tumor population killed by chemotherapy depends on the amount of drug in the 
system. The fraction killed has a maximum less than one, since only tumor cells in certain stages 
of development can be killed by chemotherapy. 
7. Circulating lymphocyte levels can be used as a measure of patient health. A fraction of NK cells, 
CD8+ T-cells, and circulating lymphocytes are also killed by chemotherapy, according to a similar 
fractional kill curve. 
8. NK and T cells are components of the process of stimulation and elimination of activated effectors 
cells, a model simplification meant to reflect the self-regulatory nature of the immune system. 
 
2.1 BASIC FORMULA & EQUATION USED IN MODEL: 
 
 This mathematical model is based on the following formula used in de Pilli’s model: 
         
 Rate of change of tumor cell population = {growth & death rate} – {cell-cell kill rate} 
                                                              And 
 Rate of change of active effectors cell population = {growth & death rate} + {recruitment  
                                                                           rate} - {Inactivation rate} 
 
 
There are four populations and three drug concentration in this model. They are tumor cells population T 
(t), natural killer cells N (t), CD8+T cells L (t), circulating lymphocytes cell𝐶1(𝑡), and concentration of 
chemotherapy drug𝐶(𝑡). Concentration of IL-2 I (t), and concentration of INF-𝛼 𝐼𝛼(t). The model modified 
expressed in the following coupled ordinary differential equations below: 
                    
𝑑𝑇
𝑑𝑡
= 𝑎𝑇(1 − 𝑏𝑇)-𝜓𝑁𝑇 − 𝐷𝑇 − 𝑃𝑇(1 − 𝑒
−𝑐)𝑇 − 𝜓′𝑇𝐿      (1) 
 
𝑑𝑁
𝑑𝑡
 = 𝑗𝐶 − 𝑘𝑁 + 𝑙
𝑇2
𝑔+𝑇2
𝑁 − 𝑒𝑁𝑇 − 𝑃𝑁(1 − 𝑒
−𝑐)𝑁       (2) 
 
𝑑𝐿
𝑑𝑡
= − 𝑛1𝐿 + 𝑓
𝐷2𝑇2
ℎ+𝐷2𝑇2
𝐿 − 𝑞𝐿𝑇 + (𝑚1𝑁 + 𝑚2𝐶1)𝑇 −𝑟𝑁𝐿
2 − 𝑃𝐿(1 − 𝑒
−𝑐)𝐿 +
𝑒𝑖𝐿𝐼
𝑙𝑖
+ 𝑣𝐿(𝑡) 
 
                                                                             (3) 
𝑑𝐶1
𝑑𝑡
= 𝛼 − 𝛽𝐶1 − 𝑃𝐶1(1 − 𝑒
−𝑐)𝐶1                                                                                                  (4) 
 
𝑑𝐶
𝑑𝑡
=  −𝛾𝑐 + 𝑣𝐶(𝑡)                                                                                                                  (5) 
 
𝑑𝐼
𝑑𝑡
  = −𝜂𝑖𝐿 − 𝜙𝐿𝐼 − 𝜇𝑇𝐼 + 𝑣𝐼(𝑡)                                                                                           (6) 
 
𝑑𝐼𝛼
𝑑𝑡
= 𝑣𝛼(𝑡) −𝑙𝐼𝛼                                                                                                                      (7) 
 
Where 𝐷 = 𝑑
(𝐿 𝑇⁄ )𝑙1
𝑆+(𝐿 𝑇⁄ )𝑙1
                                                                                                            (8) 
 
𝜓′ = 𝜓𝐶𝑇𝐿(2 − 𝑗
(−𝐼𝛼 𝐼𝛼0⁄ ))                                                                                                      (9) 
 
 
 2.2 Description about system of equations : 
                                                                                                      
The terms    
𝑑𝑇
𝑑𝑡
,
𝑑𝑁
𝑑𝑡
,
𝑑𝐿
𝑑𝑡
,
𝑑𝐶1
𝑑𝑡
,
𝑑𝐶
𝑑𝑡
,
𝑑𝐼
𝑑𝑡
,
𝑑𝐼𝛼
𝑑𝑡
  from equation (1) to equation (7) represent the growth rates of the all 
population. We discuss more detail in following: 
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 Equation(1)  ∶  
𝑑𝑇
𝑑𝑡
  {The tumor}:- 
 
Term Description 
𝑎𝑇(1 − 𝑏𝑇) Logistic tumor growth 
𝜓𝑁𝑇 NK induced tumor death 
𝐷𝑇 Tumor inactivation by CD8+T cells, where 𝐷 =
𝑑
(𝐿 𝑇⁄ )𝑙1
𝑆+(𝐿 𝑇⁄ )𝑙1
 
𝑃𝑇(1 − 𝑒
−𝑐)𝑇 Chemotherapy drug kill term, where(1 − 𝑒−𝑐)is 
saturation term. 
𝜓′𝑇𝐿 Enhancing the Tumor cell recognition. 
 
Equation(2)  ∶  
𝑑𝑁
𝑑𝑡
  {The NK-cells} :- 
 
 
𝑗𝐶 − 𝑘𝑁 Growth of NK-cells 
𝑙
𝑇2
𝑔 + 𝑇2
𝑁 
The recruitment term of NK-cells 
𝑒𝑁𝑇 Inactivation term 
𝑃𝑁(1 − 𝑒
−𝑐)𝑁 Chemotherapy drug kill term. 
 
 
   
Equation(3)  ∶  
𝑑𝐿
𝑑𝑡
  {The CD8+T-cells}:- 
 
     
𝑛1𝐿 Decrease express term of CD8+T cells. 
𝑓
𝐷2𝑇2
ℎ + 𝐷2𝑇2
𝐿 
Interaction of CD8+T cells & tumor (recruitment 
term) 
𝑞𝐿𝑇 Inactivation term 
(𝑚1𝑁 + 𝑚2𝐶1)𝑇 Recruitment term (𝑚1𝑁𝑇 + 𝑚2𝐶1𝑇 ) of NK & 
Circulating lymphocytes. 
 
𝑟𝑁𝐿2 NK-cell regulation of CD8+T cells (Inactivation 
term). 
𝑃𝐿(1 − 𝑒
−𝑐)𝐿 Chemotherapy drug kill term 
𝑒𝑖𝐿𝐼
𝑙𝑖
 
The presence of Immunotherapy drug stimulates 
the production of CD8+T-cells. 
𝑣𝐿(𝑡) Injection of TIL drug to the body. 
 
 
 
Equation(4)  ∶  
𝑑𝐶1
𝑑𝑡
  {Circulating lymphocytes}:- 
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𝛼 − 𝛽𝐶1 Circulating lymphocytes are generated a constant 
rate. 
𝑃𝐶1(1 − 𝑒
−𝑐)𝐶1 Chemotherapy drug kill term. 
Equation(5)  ∶  
𝑑𝐶
𝑑𝑡
  {Chemotherapy drug}:- 
 
𝛾𝑐 Chemotherapy drug decays exponentially (const. 
rate). 
𝑣𝐶(𝑡) Injection of Chemotherapy drug to the body. 
 Equation(6)  ∶  
𝑑𝐼
𝑑𝑡
  {Immunotherapy drug (IL-2)}:- 
 
−𝜂𝑖𝐿 − 𝜙𝐿𝐼 − 𝜇𝑇𝐼 Immunotherapy drug decays exponentially. 
                                       𝑣𝐼(𝑡)                                                                                            Injection of (IL-2)  drug to the body. 
Equation(7)  ∶  
𝑑𝐼𝛼
𝑑𝑡
 {Interferon alpha (INF-α)}:- 
 
                       𝑣𝛼(𝑡) Injection of (INF-α) drug to the body. 
                       𝑙𝐼𝛼  Immunotherapy drug decays exponentially. 
Equation  {(8) & (9)}:  
  
𝐷 = 𝑑
(𝐿 𝑇⁄ )𝑙1
𝑆 + (𝐿 𝑇⁄ )𝑙1
 
Tumor inactivation term by CD8+T cells. 
                     𝜓′ = 𝜓𝐶𝑇𝐿(2 − 𝑗
(−𝐼𝛼 𝐼𝛼0⁄ )) Interaction between (INF-α), CD8+T cells & tumor 
cells. 
 
3. Parameter Derivation - 
 
To facilitate simulations of our proposed model, it is necessary to obtain accurate parameters for our 
equations. Unfortunately there is no plethora of tumor-immune interaction data available to choose from. 
Therefore we make use of human data   by Rosenberg’s clinical trials. We then run simulations with 
parameter in order to evaluate the behavior of our model. 
 
3.1 Chemotherapy Drug Parameters : 
 
We estimate the values of the kill parameters 𝑃𝑇 ,𝑃𝑁, 𝑃𝐿  & 𝑃𝐶1  based on the log-kill hypothesis. We then 
assume the drug strength to be one log-kill, as described in [27]. 𝑃𝑁, 𝑃𝐿  & 𝑃𝐶1  Are assumed to be smaller 
than𝑃𝑇 , but similar in magnitude, since immune cells are one of the most rapidly dividing normal cell 
populations in the body. We calculate the drug decay rate,  𝛾 , from the drug half-life and the relation 
𝛾 =
𝑙𝑜𝑔2
𝑡1 2⁄
.  We estimated the drug half-life 𝑡1 2⁄  to be more than 18 hours, based on the chemotherapeutic 
drug doxorubicin [9]. 
 
3.2 Immunotherapy Drug Parameters : 
 
In addition to the original model that includes a chemotherapy differential equation, we introduce a 
immunotherapy drug into our system of differential equations. The cytokine Interleukin 2 (IL-2) simulates 
CD8+ T cell proliferation. It has been administered in clinical trials on its own, in combination with 
chemotherapy, as well as after a TIL (tumor infiltrating lymphocyte) injection, in which a large number of    
highly activated CD8+ T cells are added to the system at a certain point in time. In order to incorporate this 
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type of immunotherapy into our model, we create a new variable for IL-2 concentration over time, and 
adjust the CD8+T cell population variable accordingly. 
Our three new parameters, 𝑒𝑖 ,𝑙𝑖, 𝜂𝑖 come from Kirschner’s model with minor alterations to adapt to the fact 
that we are only concerned with the amount of IL-2 that is not naturally produced by the immune system. 
Since the presence of IL-2 in the body stimulates the production of CD8+ T cells, we include a Michaelis-
Menton term for the CD8+T cell growth rate induced by IL-2. The drug equation for IL-2 is identical in 
form to our chemotherapy term, and its half-life, 𝜂𝑖  is taken from Kirschner’s model as well [24]. 
 
3.3 Additional Regulation Parameters : 
 
The values of 𝑚2 and 𝑟 are based on reasonable simulation outcomes of our model. The conditions we set 
on 𝑟 are that the term 𝑟𝑁𝐿2  must be smaller in magnitude, for most tumor burdens, than the negative terms 
that involved the tumor population in our equation for dL/dt. Our reason for this is primarily qualitative 
since NK cells only eliminate CD8+T cells in excess or in the absence of a tumor burden. 
 
3.4 Human parameters : 
 
The values shown in Table-1 and Table-2 are sets of human parameters that originate from the curve fits 
created by dePillis et al. [13], patients from clinical trials [20], as well as from an additional and similar 
tumor model [26]. We obtain the values of  𝑏, 𝜓, 𝑇, 𝑙1, 𝑘, 𝑙, 𝑔, 𝑓, 𝑛1, 𝑒, 𝑚1 and 𝑠 from data collected from 
patient 1 in a clinical trial for Biochemotherapy [13], [20]. We use the value of a from curve fits by dePillis 
et al. and this parameter is strictly for tumor growth and is independent of the human immune cells. We 
take the values of additional parameters 𝑘 and 𝑔 from Kuzenetsov’s tumor-immune model. 
 
𝑎 = 0.43078                𝑏 = 1 × 10−9           𝑐 = 6.41 × 10−11 
 
𝑗 = 2.08 × 10−7           𝑘 = 0.0412                𝑙 = 0.01245 
 
𝑔 = 2.019 × 107           𝑓 = 0.0249                ℎ = 3.66 × 107 
 
𝑚1  = 1.1 × 10
−7         𝑃𝑇    = 0.9                  𝑃𝑁,  = 0.6 
 
𝑃𝐿  = 0.6                        𝑃𝐶1   = 0.6                  𝑟 = 3 × 10
−10 
 
𝛼 = 7.5 × 108              𝛽 = 0.012                  𝛾 = 0.9 
 
𝑒𝑖  = 0.1245                   𝑙𝑖 = 2 × 10
7              𝜂𝑖   = 10 
 
Table 1:  Model parameters shared by Patient 1 and Patient 2 [13, 20, and 24] 
 
The value of 𝑞 that we use in our model is similar in magnitude to that of dePillis etal. However we adjust 
it accordingly after the addition of the new 𝑚1, 𝑚2 and 𝑟 terms in the dL/dt equation. 
In order to calculate 𝛼 and 𝛽 for the human population, we estimate the amount of blood in the average 
human to be 5 liters [12]. Based on a typical white blood cell count for humans of 4.2 × 1010, and the 
percentage made up of circulating lymphocytes of about 25% to 70%  of white blood cells [23]. Therefore 
we obtain an equilibrium number of circulating lymphocytes of 6.25 × 1010. Once we find the lifespan of 
circulating lymphocytes [10], we take the reciprocal to find𝛽. We then use the equilibrium solution of the 
differential equation for 𝑐1 in the absence of treatment, 6.5 × 10
10  = 𝑐1𝑒𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚 = 𝛼 / 𝛽, to calculate𝛼. 
We then use the equilibrium number of circulating lymphocytes to convert the parameter 𝑗 from [13] to our 
new model, according to  𝑗𝑜𝑙𝑑  / 𝑐1𝑒𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚 = 𝑗.  
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3.5 Parameter Investigation : 
 
We use these sets of parameters to produce simulations for our model and determine its qualitative 
behavior. Choosing a variety of parameter sets allows us to test our model with several sets of experimental 
data and take a closer look at patient specific behavior. 
 
                   Patient -1                                                                 Patient-2 
 
    𝑇  = 2.3389               𝑙1 = 2.0922                      𝑇     = 1.8792                𝑙1  = 1.8144  
 
    ℎ = 3.66 × 107        𝑛1= 0.2044                      ℎ   = 5.66 × 10
7          𝑛1 = 9.1238 
 
    𝑒 = 3.422 × 10−6     𝑞 = 1.422  × 10−6           𝑒  = 3.593 × 10−6       𝑞  = 1.593 × 10−6 
 
    𝑚2 = 2 × 10
−11       𝑠   = 0.0839                     𝑚2    = 6.81 × 10
−10   𝑠  = 0.512 
 
 
Table 2: Model parameters that differ between Patient -1 and Patient -2 [13, 20, 24]. 
 
4.  Model Behavior & Accuracy - 
 
We test the behavior and accuracy of our model with experimental results of two patients in 
Rosenberg’s study on metastatic melanoma [20]. We modified our additional parameters,  𝑚2 and 𝑟, to fit 
these results. First we examine the model with the set of parameters provided in Table 2, which is taken 
from results of Rosenberg’s clinical trials. We discover a case where a healthy immune system can control 
a tumor that a weak immune system cannot, a case where chemotherapy or immunotherapy can kill a tumor 
burden, and a case where combination therapy is essential to the survival of the patient. We then compare 
these results for patient 1 to the behavior of our model with patient 2 and described by following graphs. 
. 
 
                (A)                                                              (B) 
      
 
 
 Fig.1 (A):- A healthy immune system effectively kills a small tumor. Initial Conditions:  106 Tumor cells,  
105    NK cells, 102  CD8+ T cells, 6 × 1010 circulating lymphocytes.    
 Parameters for this simulation are documented in Table 2.  
(B):- A depleted immune system fails to kill a small tumor when left untreated. Initial      Conditions: 106  
Tumor cells, 103  NK cells, 10 CD8+ T cells, 6 × 109 circulating      lymphocytes. Parameters for this 
simulation are documented in Table 2 
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(A)                                                      (B) 
 
Fig.2 (A):- A case where three doses of chemotherapy is enough to kill off a tumor. Initial Conditions: 2 
× 107 tumor cells, 1 × 103NK cells, 10 CD8+ T cells, 6 × 109 circulating lymphocytes. 
(B):- A 109 cell tumor is not killed by the body with only the aid of chemotherapy.  
Parameters for this simulation are documented in Table 2.  
 
 
(A)                                                                  (B) 
Fig.3 (A):-Combination therapy is effective in eliminating a tumor burden of 109 cells. 
(B):-Combination therapy is ineffective for a tumor burden of size  109 . Parameters for this                   
simulation are documented in Table 2.  
 
4.1 Comparison with Patient -2 : 
 
In order to look at how much these treatment simulations vary from patient to patient, we change patient 
specific parameters from Rosenberg’s study, and run similar experimental simulations with the parameters 
for patient-2. These parameters are presented in Table2. 
First we repeat the experiment simulated in Fig.1 (A) for a tumor burden of size that the immune system in 
a healthy state can kill on its own in patient 1. Healthy immune system conditions that killed the tumor in 
patient 1 are ineffective at treating the same size tumor in patient-2 (see Fig.4 (A)). Patient 2’s immune 
system is able to handle a tumor of size 105 under the same immune cell count, as we show in Fig.4 (B). 
Unfortunately, the immune system’s tumor handling capacity appears very patient specific, which should 
be unsurprising since the combination therapy administered to 13 patients in Rosenberg’s study [20], was 
only effective at treating two patients. 
In addition to the differing results of the immune system alone, we examine the initial conditions where 
chemotherapy was effective at treating a tumor of size 106 with a weak immune system for patient1. This 
same simulation with patient 2’s parameters yields a different result. Again, the tumor is not killed in this 
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situation, shown in Fig.5. We also perform simulations of immunotherapy and combination therapy on 
patient 2 for a tumor of size 106   for the weak immune system. As shown inFig.6, immunotherapy is 
ineffective at killing this tumor burden. In fact, patient-2 needs combination therapy with pulsed 
chemotherapy for 100 days before the tumor is eliminated (see Fig.7). In this case it is a good idea to 
administer more immunotherapy treatment, involving additional doses of IL-2. This expansion in treatment 
is effective at speeding tumor death. For example, if we allow for three additional days of IL-2 doses of 
immunotherapy, with drug treatment, the tumor will die in less than thirty days (see Fig.8). 
 
 
 
(A)                                                                   (B) 
 
Fig.3 (A):- Immunotherapy is able to kill a tumor burden of size 106 cells.  109 TILs are administered   
from day 7 through 8. IL-2 is administered in 6 pulses from day 8 to day 10. 
(B):- Immunotherapy is unable to kill a tumor burden of size 109  cells.  109  TILs are administered from 
day 7 through 8. IL-2 is administered in 6 pulses from day 8 to day 11. 
Parameters for this simulation are provided in Table 2. 
 
. 
 
 
(A)                                                         (B) 
 
Fig.4 (A):- Patient -2 cannot kill a 106 cell tumor with a healthy immune system of 105 NK cells, 100 
CD8+T cells, and 6 × 1010 circulating lymphocytes. Parameters for this simulation are provided in Table 
2.   
(B):- Patient -2 kills a 105 cell tumor with a healthy immune system of 105  NK cells, 100 CD8+T cells, 
and 6 × 1010 circulating lymphocytes. 
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Fig.5: Pulsed chemotherapy fails to kill the 106  cell tumor in patient 10, even with a healthy immune 
system of 105 NK cells, 100 CD8+ T cells, and 6 × 1010 circulating lymphocytes. The parameters for this 
simulation are provided in Table 2.              
 
Fig.6: TIL and IL-2 immunotherapy fails to kill the 106  cell tumor in patient 10, even with a healthy 
immune system of 105 NK cells, 100 CD8+ T cells, and 6 × 1010  circulating lymphocytes. 3 × 108 TIL 
cells are injected on day 7 through 8. IL-2 is pulsed 4 times between day 8 and day 10. The parameters for 
this simulation are provided in Table 2. 
 
 
 
Fig.7: Combination therapy kills the 106 cell tumor in patient 10. The initial conditions for the immune 
system are 105  NK cells, 100 CD8+ T cells, and 6 × 1010   circulating lymphocytes. Chemotherapy is 
pulsed 3/10 days as in Fig.5 and immunotherapy is administered as in Fig.6. The parameters for this 
simulation are provided in Table 2. 
 
Fig.8: Combination therapy kills the 106 cell tumor in patient 10 quicker than in Fig.7 the initial conditions 
for the immune system are 105  NK cells, 100 CD8+ T cells, and 6 × 1010  circulating lymphocytes. 
Chemotherapy is pulsed 3/10 days for 15 days. Immunotherapy is administered for longer: 108 TILs from 
day 7 through 8, and then pulses of IL-2 from day 8 through 13.5. The parameters for this simulation are 
provided in Table 2. 
 
Since the tumor almost dies within 15 days, we ended the pulsed chemotherapy cycle at that point. 
However, we do see a relapse in tumor growth once we end chemotherapy. The tumor appears to arise out 
of nowhere after chemotherapy treatment ends in Fig.8; however the immune system is now strong enough 
to keep it in control. 
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5. Discussion and Conclusion - 
 
We applied a model developed by de Pillis’s and colleagues (2009) in the form of a system of 
coupled ordinary differential equation. Then we extended this model to include the presence of INF-
The model used to investigate effect of TIL, IL-2, and INF-
influence of immunotherapy, chemotherapy and biochemotherapy. Our simulation shown that the 
treatments play important role to remission or even to kill the tumor cells completely. 
In the first our simulation, we examine an initial size of tumor cells is106. This simulation shows 
the immune system has not become activated to kill the tumor cells. For this tumor, immune system 
strength is very important in determining whether or not the immune system alone can kill a tumor. The 
first specifies what we will denote as an initially immune system with105, natural killer cells, 102 CD8+ T-
cells, and 6 × 1010   circulating lymphocytes [6]. As seen in Figure 1A, the innate immune response is 
sufficiently strong to control the tumor. However, when the immune system is weakened, a tumor of the 
same size grows to a dangerous level in the absence of treatment interventions. Simulated results for this 
weakened immune case, with initial conditions set to 103   natural killer cells, 10 CD8+ T-cells, and 6 
× 108 circulating lymphocytes, are shown in Figure 1B. Similar with the case patient 1, our simulation for 
patient 2 shown that biochemotherapy able to kill tumor cells 106  until 107, are shown in Figure 5. But 
immunotherapy and chemotherapy is unable to kill tumor cells 106 . As shown in Figure 3 (B), 
immunotherapy cause reduction the tumor cells until clean completely on day 10 and then relapsed on day 
30 to level dangerous, instead chemotherapy is unable to kill this tumor size, as shown in Figure 4(B). 
This work is still necessary to investigation on how the effect of drug injection for another cells or 
how the effect another cytokines such as IL-4, IL-10 and IL-12 in future. 
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